Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: NR2B NMDA receptor antagonists - Evotec SE

Drug Profile

Research programme: NR2B NMDA receptor antagonists - Evotec SE

Alternative Names: ENS 102; EVT 100 series; EVT 102; NR2B-selective NMDA receptor antagonists; RO-631908

Latest Information Update: 27 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Evotec SE
  • Class Phenols; Piperidines; Small molecules
  • Mechanism of Action NR2B N-Methyl-D-Aspartate antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Neuropathic pain; Postoperative pain

Most Recent Events

  • 01 Aug 2016 Janssen Pharmaceuticals terminates its licence for NR2B selective NMDA antagonist
  • 31 Dec 2011 Discontinued - Preclinical for Alzheimer's disease in Germany (PO)
  • 31 Dec 2011 Discontinued - Preclinical for Neuropathic pain in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top